Dawn M. Cooper et al. Hemostatic powder TC-325 as first-line treatment option for
malignant gastrointestinal bleeding: a cost–utility analysis in the United Kingdom
The cost-effectiveness of a hemostatic powder (TC-325) was compared with standard
endoscopic therapy as firstline treatment for malignant upper gastrointestinal bleeding
(MUGIB) in the United Kingdom. Based on data pooled from three randomized controlled
trials, TC-325 was relatively cost saving (£245.88 less per patient, i. e. 5% reduction)
with an incremental increase in quality-adjusted life years (0.001). These findings
can assist in the selection of endoscopic treatment modalities for MUGIB.
